Persistent eustachian valve

Summary

Persistent eustachian valve (MONDO:0020449) is a disease. A subtype of congenital anomaly of the inferior vena cava — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	persistent eustachian valve
Mondo ID	MONDO:0020449
Orphanet	99120
UMLS	C5190784
MedGen	1678657
GARD	0019661
Is cancer (heuristic)	no

Disease family

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › vascular disorder › congenital anomaly of the inferior vena cava › persistent eustachian valve

Related subtypes (5): right inferior vena cava connecting to left-sided atrium, azygos continuation of the inferior vena cava, congenital stenosis of the inferior vena cava, inferior vena cava interruption, primary inferior vena cava aneurysm

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.